Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.
Membranous nephropathy (MN) post allogeneic hematopoietic stem cell transplantation (HSCT) is a rare complication with few long-term outcome data. We describe the clinical course and outcome of an adult female patient who developed MN after allogeneic HSCT for follicular non-Hodgkin's lymphoma. MN was treated with methylprednisolone as first-line therapy, then she was changed to rituximab for a relapse. After treatment with rituximab, we observed a progressive decrease of proteinuria and normalization of serum albumin. Seven months after treatment, she remains in remission. No adverse reactions to rituximab were observed throughout follow-up.
Vischini
Gisella
G
Nephrology and Dialysis Unit, Oncohematology and Transplantation Department, Tor Vergata University, Rome, Italy. gisella.v1979@libero.it
Cudillo
Laura
L
Ferrannini
Michele
M
Di Daniele
Nicola
N
Cerretti
Raffaella
R
Arcese
William
W
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy* / Q000209:etiology*; D005938:Glucocorticoids / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery; D008775:Methylprednisolone / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D008775:Methylprednisolone